Samsung and Pfizer Expand Collaboration to Accelerate Biosimilar Production
July 5, 2023
Samsung Biologics and Pfizer have announced they are expanding their current collaboration to ramp up production of biosimilars, bringing the agreement to a value of $897 million. The announcement comes as Pfizer and another branch of Samsung both prepare for US launches of their Humira biosimilars.
According to Kevin Dunleavy, “Work for Pfizer will be conducted in Samsung’s Plant 4 in Incheon, which was due for completion last month, the company said. Earlier this year, the company said it was starting construction on its $1.46 billion Plant 5, the first of four manufacturing buildings at its Bio Campus II.”
To read more, click here.
(Source: Fierce Pharma, July 5th, 2023)
